Known targets — ChEMBL curated mechanism
DRD2DRD3DRD4GNRHRHRH1HTR2AHTR2CSLC6A2SLC6A4SSTR1SSTR2SSTR3SSTR5
The experimentally established mechanism targets of Pamoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | ME2 | P23368 | 1/20 | 0.76 |
| ▸ | ME1 | P48163 | 1/20 | 0.76 |
| ▸ | ME3 | Q16798 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 7/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.56 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.52 |
| ▸ | GALK1 | P51570 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pamoic Acid SCHEMBL30293211 | 1.00 | GPR35 (1.00) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL30293206 | 1.00 | GPR35 (1.00) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL5721 | 1.00 | GPR35 (1.00) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL29362189 | 1.00 | GPR35 (1.00) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL991085 | 0.98 | GPR35 (0.97) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL9982931 | 0.98 | GPR35 (0.97) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL5175194 | 0.98 | GPR35 (0.97) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL1055608 | 0.98 | GPR35 (0.97) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL5012888 | 0.98 | GPR35 (0.97) | GPR35POLBME2ME1ME3 | |
| Pamoic Acid SCHEMBL15009319 | 0.98 | GPR35 (0.97) | GPR35POLBME2ME1ME3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3347011-A1 | MUSCARINIC COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | Chase Pharmaceuticals Corporation (US) | 2018-07-18 | — | — | EP | disclosed |
| WO-2017044693-A1 | MUSCARINIC COMBINATION AND ITS USE FOR COMBATING HYPOCHOLINERGIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CHASE PHARMACEUTICALS CORPORATION (US) | 2017-03-16 | — | — | WO | disclosed |
| US-20120065067-A1 | PAMOIC ACID BLOCKS ETHYLENE SIGNALING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065067-A1 | PAMOIC ACID BLOCKS ETHYLENE SIGNALING | PAM, PRKAA1, PRKAA2 | GPR35 2779/4885POLB 2224/4885ME2 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.